DZDan Zhou

Dan Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Caiyun Qian

    Department of Blood Transfusion, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication
  • Daya Luo

    The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China.

    1 shared publication
  • Jiayi Zhang

    School of Queen Mary, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication
  • Renzhuo Gao

    School of Queen Mary, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication
  • Xiaohong Yang

    School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication
  • Xingpeng Qiu

    School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication

Latest Publications

  • Open Access

    Cancer Therapeutic Potential and Prognostic Value of the SLC25 Mitochondrial Carrier Family: A Review

    by Renzhuo Gao, Dan Zhou, Xingpeng Qiu, Jiayi Zhang, Daya Luo, Xiaohong Yang, Caiyun Qian, Zhuoqi Liu

    Transporters of the solute carrier family 25 (SLC25) regulate the intracellular distribution and concentration of nucleotides, amino acids, dicarboxylates, and vitamins within the mitochondrial and cytoplasmic matrices. This mechanism involves changes in mitochondrial function, regulation of cellular metabolism, and the ability to provide energy. In this review, important members of the SLC25 family and their pathways affecting tumorigenesis and progression are elucidated, highlighting the diversity and complexity of these pathways. Furthermore, the significant potential of the members of SLC25 as both cancer therapeutic targets and biomarkers will be emphasized.